Dialysis patients may get better vaccine protection with a common transplant drug
NCT ID NCT07587801
First seen May 18, 2026 · Last updated Jun 23, 2026 · Updated 4 times
Summary
This study tests whether taking a short course of the drug sirolimus (Rapamycin) can improve how well older adults on hemodialysis respond to flu and RSV vaccines. Sixty participants will receive the vaccines plus sirolimus at different times. The goal is to see if this approach strengthens immune memory against these viruses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OLDER ADULTS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Princess Alexandra Hospital
Woolloongabba, Queensland, 4102, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Royal Adelaide Hospital
Adelaide, South Australia, 5000, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Royal Prince Alfred Hospital
Camperdown, New South Wales, 2050, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sirolimus (Rapamycin)
What this could lead to
If it works, this could point toward a way to improve vaccine protection for people with weakened immune systems, like those on dialysis.
What could go wrong
This is a small, early-phase trial (60 people) and the drug may not improve vaccine response or could cause side effects. Results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.